These launches are what Oelrich called “must-win battles” at Bayer as the Xarelto loss of exclusivity reaches “full swing” in ...
Bayer AG plans to push pause on some of its pharmaceutical dealmaking, focusing instead on reducing the high debt load the ...
Growth is on the horizon for German drug conglomerate Bayer (BAYRY), despite “falling sales of its blockbuster blood thinner Xarelto,”amid ...
Top doctors raised concerns about domestically made drugs, saying Beijing’s effort to lower costs is sacrificing quality.
An experimental menopause drug from Bayer succeeded in a late-stage trial in women taking drugs to treat or prevent breast cancer, the company said Thursday. Bayer said the drug, elinzanetant ...
This health news update covers Bayer's $100 million payout over PCBs, Biogen's future strategy, Pfizer's appeal in an SEC ...
The trend toward larger deal sizes is likely to continue as companies seek to bolster their pipelines amid a looming patent ...
Chinese regulators are investigating the quality of domestic generic drugs after a rare public backlash against a cost-cutting campaign that prioritised their use in the national healthcare system but ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback